flurbiprofen

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Dose	Unit	Route
0.20	g	O
0.20	g	R
44	mg	O

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.90 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	17.55 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	92 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.992		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.465		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	188.365	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	12.560	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	0.390	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	1.400	%	High	1
herg	hERG pIC50	4.200	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	8.222	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	3.508	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	0.480	%	High	1
kinase-safety-class	ACVR2B,AXL,EIF2AK3,GRK2,PDK1,PDK2,PDK4,PIK3CG,PRKDC,TGFBR1	10
kinase-selectivity-class	AXL	1
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.517		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	77.804		High	1
mppb	Mouse plasma protein binding (% unbound)	3.470		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.222		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	1.160	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	9.419	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	84.210	%	High	1
rppb	Rat plasma protein binding (% unbound)	0.620	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	950.605	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	131.70	23.74	55	2641	64821	90560930
Toxic anterior segment syndrome	99.87	23.74	21	2675	2229	90623522
Acute kidney injury	85.91	23.74	73	2623	320314	90305437
Allergy test positive	76.39	23.74	14	2682	728	90625023
Central pain syndrome	71.30	23.74	13	2683	657	90625094
Drug reaction with eosinophilia and systemic symptoms	63.09	23.74	29	2667	42729	90583022
Eyelid oedema	57.68	23.74	19	2677	11515	90614236
Pancreatitis acute	44.92	23.74	21	2675	32094	90593657
Lip oedema	41.75	23.74	12	2684	4627	90621124
Hyperaesthesia	35.57	23.74	13	2683	10689	90615062
Eosinophilic myocarditis	33.90	23.74	7	2689	678	90625073
Urticaria	33.90	23.74	44	2652	312690	90313061
Altered state of consciousness	33.24	23.74	17	2679	31515	90594236
Ankylosing spondylitis	32.98	23.74	13	2683	13120	90612631
Dermo-hypodermitis	32.76	23.74	7	2689	800	90624951
Poisoning deliberate	30.13	23.74	13	2683	16473	90609278
Gingival pain	29.41	23.74	11	2685	9641	90616110
Somnolence	26.76	23.74	32	2664	209052	90416699
Anastomotic complication	26.05	23.74	5	2691	334	90625417
Hepatic cytolysis	25.07	23.74	14	2682	30902	90594849

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypertrophic cardiomyopathy	56.94	28.14	12	1114	1453	42618756
Ischaemic cerebral infarction	55.57	28.14	12	1114	1631	42618578
Toxic anterior segment syndrome	34.99	28.14	8	1118	1408	42618801
Arrhythmia	34.08	28.14	18	1108	40299	42579910
Sudden death	31.55	28.14	13	1113	16616	42603593
Abnormal dreams	28.50	28.14	10	1116	8261	42611948

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

flurbiprofen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	165.55	20.77	75	3515	98425	110487284
Toxic anterior segment syndrome	132.34	20.77	29	3561	3425	110582284
Allergy test positive	72.11	20.77	14	3576	909	110584800
Central pain syndrome	67.53	20.77	13	3577	807	110584902
Urticaria	65.20	20.77	65	3525	318792	110266917
Eyelid oedema	58.24	20.77	21	3569	15241	110570468
Drug reaction with eosinophilia and systemic symptoms	55.37	20.77	34	3556	82061	110503648
Lip oedema	51.04	20.77	16	3574	7584	110578125
Cross sensitivity reaction	47.11	20.77	14	3576	5553	110580156
Acute kidney injury	46.84	20.77	78	3512	635352	109950357
Ischaemic cerebral infarction	46.11	20.77	12	3578	2933	110582776
Hypertrophic cardiomyopathy	45.26	20.77	12	3578	3151	110582558
Pancreatitis acute	38.19	20.77	24	3566	60250	110525459
Ankylosing spondylitis	32.99	20.77	14	3576	15598	110570111
Hyperaesthesia	30.44	20.77	13	3577	14714	110570995
Face oedema	28.15	20.77	16	3574	33453	110552256
Dermo-hypodermitis	27.89	20.77	7	3583	1481	110584228
Sudden death	27.03	20.77	14	3576	24381	110561328
Eosinophilic myocarditis	25.55	20.77	7	3583	2078	110583631
Arrhythmia	23.76	20.77	19	3571	69556	110516153
Gingival pain	23.29	20.77	11	3579	15725	110569984
Poisoning deliberate	23.26	20.77	13	3577	26318	110559391
Anastomotic complication	22.67	20.77	5	3585	606	110585103
Altered state of consciousness	22.42	20.77	17	3573	57609	110528100
Abnormal dreams	22.25	20.77	10	3580	12770	110572939
Electrocardiogram QT prolonged	21.80	20.77	22	3568	108938	110476771
Toxicity to various agents	21.70	20.77	48	3542	480507	110105202
Intentional overdose	21.62	20.77	24	3566	132477	110453232
Spinal pain	21.59	20.77	11	3579	18504	110567205
Laryngeal oedema	21.41	20.77	9	3581	9798	110575911

Source	Code	Description
ATC	M01AE09	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Propionic acid derivatives
ATC	M02AA19	MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Antiinflammatory preparations, non-steroids for topical use
ATC	R02AX01	RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Other throat preparations
ATC	S01BC04	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFLAMMATORY AGENTS Antiinflammatory agents, non-steroids
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018712	Analgesics, Non-Narcotic
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory drug
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35481	non-narcotic analgesic
CHEBI has role	CHEBI:35493	antipyretic
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35544	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:75835	anti-anaemic agent
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Osteoarthritis	indication	396275006
Prevention of Ocular Surgery-Induced Miosis	indication
Dysmenorrhea	off-label use	266599000
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Body fluid retention	contraindication	43498006
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Gastrointestinal perforation	contraindication	51875005
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Gastrointestinal hemorrhage	contraindication	74474003
Kidney disease	contraindication	90708001	DOID:557
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Impaired wound healing	contraindication	271618001
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Smokes tobacco daily	contraindication	449868002
Ocular Bleeding	contraindication

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR	IC50	8.39	WOMBAT-PK	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN	INHIBITOR	IC50	8.74	WOMBAT-PK	CHEMBL
Aldo-keto reductase family 1 member C1	Enzyme	Q04828	AK1C1_HUMAN		IC50	5.69	CHEMBL
Aldo-keto reductase family 1 member C2	Enzyme	P52895	AK1C2_HUMAN		IC50	4.49	CHEMBL
Aldo-keto reductase family 1 member C3	Enzyme	P42330	AK1C3_HUMAN		IC50	5.81	CHEMBL
Fatty acid-binding protein, intestinal	Cytosolic other	P12104	FABPI_HUMAN		Ki	4.59	CHEMBL
Aldo-keto reductase family 1 member C4	Enzyme	P17516	AK1C4_HUMAN		IC50	5.53	CHEMBL
Fatty acid-binding protein, liver	Cytosolic other		FABPL_RAT		Ki	5.93	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_MOUSE		IC50	6.30	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_SHEEP		Ki	6	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_RAT		IC50	6.77	CHEMBL

ID	Source
4019154	VUID
N0000147399	NUI
D00330	KEGG_DRUG
1584155-62-3	SECONDARY_CAS_RN
4019153	VANDF
4019154	VANDF
C0016377	UMLSCUI
CHEBI:5130	CHEBI
FLP	PDB_CHEM_ID
CHEMBL563	ChEMBL_ID
DB00712	DRUGBANK_ID
CHEMBL3989754	ChEMBL_ID
D005480	MESH_DESCRIPTOR_UI
3394	PUBCHEM_CID
4194	IUPHAR_LIGAND_ID
3220	INN_ID
5GRO578KLP	UNII
4502	RXNORM
4753	MMSL
4754	MMSL
72	MMSL
d00239	MMSL
002382	NDDF
003968	NDDF
11633008	SNOMEDCT_US
373506008	SNOMEDCT_US
54344006	SNOMEDCT_US
5GRO578KLP	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
FLURBIPROFEN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-096	TABLET, FILM COATED	100 mg	ORAL	ANDA	11 sections
Flurbiprofen Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	21695-615	SOLUTION/ DROPS	0.24 mg	OPHTHALMIC	ANDA	20 sections
Flurbiprofen Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	24208-314	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	20 sections
FLURBIPROFEN SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	42254-023	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	NDA authorized generic	18 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	43063-992	TABLET, FILM COATED	100 mg	ORAL	ANDA	26 sections
Flurbiprofen Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3946	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	20 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3362	TABLET, FILM COATED	100 mg	ORAL	ANDA	27 sections
Flurbiprofen Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	63187-937	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	20 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	64950-218	TABLET	100 mg	ORAL	ANDA	29 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2480	TABLET, FILM COATED	100 mg	ORAL	ANDA	26 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	68071-4436	TABLET, FILM COATED	100 mg	ORAL	ANDA	27 sections
Flurbiprofen	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7341	TABLET, FILM COATED	100 mg	ORAL	ANDA	26 sections
Flurbiprofen Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	69292-722	SOLUTION/ DROPS	0.30 mg	OPHTHALMIC	ANDA	20 sections
Antiphlamine Pain Relieving	HUMAN OTC DRUG LABEL	1	69642-1300	PATCH	33 mg	TOPICAL	unapproved drug other	8 sections
LURBIRO	HUMAN PRESCRIPTION DRUG LABEL	1	71085-082	TABLET	100 mg	ORAL	ANDA	29 sections
Rinol-STroche	HUMAN OTC DRUG LABEL	1	72988-0041	TROCHE	8.75 mg	ORAL	unapproved drug other	7 sections